NCT02807077View on ClinicalTrials.gov

PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Myelofibrosis
Interventions
DRUG

Pacritinib

Group 1, 2, 3, and 5 will be administered single oral 400-mg dose of pacritinib. Subjects in the Group 4 received a single 400-mg dose of pacritinib during two different treatment periods: Dialysis and Inter-Dialysis

Trial Locations (3)

D-81241

APEX GmbH, Munich

MD-2025

Republican Clinical Hospital, Chisinau

Unknown

Carol Davila Nephrology Hospital Bucharest, Bucharest

Sponsors

Lead Sponsor

CTI BioPharma
All Listed Sponsors
collaborator

SGS S.A.

INDUSTRY

lead

CTI BioPharma

INDUSTRY

NCT02807077 - PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects | Biotech Hunter | Biotech Hunter